Ticker	Volume	Price	Price Delta
DJIA	15,303.10	+8.60	0.06%
S&P 500	1,649.60	-0.91	-0.06%
Nasdaq	3,459.14	-0.27	-0.01%

Ticker

Volume

Price

Price Delta

DJIA

15,303.10

+8.60

0.06%

S&P 500

1,649.60

-0.91

-0.06%

Nasdaq

3,459.14

-0.27

-0.01%

Ticker	Volume	Price	Price Delta
STOXX 50	2,764.29	-12.49	-0.45%
FTSE 100	6,654.34	-42.45	-0.63%
DAX	8,305.32	-46.66	-0.56%

Ticker

Volume

Price

Price Delta

STOXX 50

2,764.29

-12.49

-0.45%

FTSE 100

6,654.34

-42.45

-0.63%

DAX

8,305.32

-46.66

-0.56%

Ticker	Volume	Price	Price Delta
Nikkei	14,612.50	+128.47	0.89%
Hang Seng	22,618.70	-51.01	-0.23%
S&P/ASX 200	4,983.50	-78.95	-1.56%

Ticker

Volume

Price

Price Delta

Nikkei

14,612.50

+128.47

0.89%

Hang Seng

22,618.70

-51.01

-0.23%

S&P/ASX 200

4,983.50

-78.95

-1.56%

Medicines Co. Settles Patent Suit With APP Over Generic Copy of Angiomax

By Phil Milford - 2012-01-23T17:51:27Z

Medicines Co. (MDCO) and Fresenius (FRE)’s APP Pharmaceuticals Inc. (APPX) settled litigation over patents for the Angiomax anticoagulant drug, with Medicines agreeing to pay $30 million to license some APP drugs.

Medicines Co., based in Parsippany, New Jersey, sued Schaumburg, Illinois-based APP in October 2009 IN Wilmington, Delaware, federal court alleging patent infringement for plans to market a generic copy of Angiomax. APP announced the settlement today.

“The settlement agreement includes a license by The Medicines Co. to APP” to sell generic Angiomax in the U.S. starting May 1, 2019, Medicines said in a statement.

Medicines will pay APP $30 million for a non-exclusive license “to sell 10 specified generic products” to hospitals and suppliers until Jan. 22, 2022, according to a Medicines filing with the U.S. Securities and Exchange Commission.

The case is The Medicines Co. v. APP Pharmaceuticals, 09- CV-00752, U.S. District Court, District of Delaware (Wilmington).

To contact the reporter on this story: Phil Milford in Wilmington, Delaware, at pmilford@bloomberg.net.

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net.

More News:

Law ·
Health Care

Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.